News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,683 Results
Type
Article (39060)
Company Profile (278)
Press Release (644345)
Section
Business (203894)
Career Advice (1985)
Deals (35362)
Drug Delivery (84)
Drug Development (80806)
Employer Resources (168)
FDA (16086)
Job Trends (14798)
News (344563)
Policy (32431)
Tag
Academia (2537)
Alliances (49077)
Alzheimer's disease (1215)
Approvals (16005)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11466)
Biotechnology (197)
Breast cancer (108)
Cancer (906)
Cardiovascular disease (81)
Career advice (1656)
Cell therapy (201)
Clinical research (63945)
Collaboration (328)
Compensation (168)
COVID-19 (2522)
Cystic fibrosis (78)
Data (862)
Diabetes (134)
Diagnostics (6097)
Earnings (84179)
Employer resources (146)
Events (108930)
Executive appointments (248)
FDA (16531)
Funding (291)
Gene therapy (149)
GLP-1 (559)
Government (4319)
Healthcare (18661)
Infectious disease (2597)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16272)
Job creations (3622)
Job search strategy (1415)
Layoffs (409)
Legal (7848)
Lung cancer (155)
Manufacturing (152)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19112)
Metabolic disorders (364)
Neuroscience (1456)
NextGen Class of 2024 (6499)
Non-profit (4463)
Northern California (1214)
Obesity (216)
Opinion (176)
Patents (94)
People (56144)
Phase I (19844)
Phase II (28155)
Phase III (21017)
Pipeline (212)
Postmarket research (2553)
Preclinical (8441)
Radiopharmaceuticals (234)
Rare diseases (180)
Real estate (5890)
Regulatory (21442)
Research institute (2318)
Resumes & cover letters (349)
Southern California (1085)
Startups (3565)
United States (11720)
Vaccines (537)
Weight loss (160)
Date
Today (240)
Last 7 days (853)
Last 30 days (2980)
Last 365 days (35697)
2024 (30485)
2023 (40083)
2022 (51197)
2021 (55721)
2020 (54104)
2019 (46553)
2018 (35034)
2017 (32127)
2016 (31500)
2015 (37569)
2014 (31334)
2013 (26375)
2012 (28592)
2011 (29279)
2010 (27352)
Location
Africa (713)
Arizona (187)
Asia (37047)
Australia (6046)
California (2744)
Canada (1180)
China (209)
Colorado (119)
Connecticut (123)
Europe (79309)
Florida (396)
Georgia (100)
Illinois (308)
Indiana (179)
Kansas (95)
Maryland (516)
Massachusetts (2250)
Michigan (144)
Minnesota (250)
New Jersey (829)
New York (844)
North Carolina (665)
Northern California (1214)
Ohio (127)
Pennsylvania (750)
South America (1091)
Southern California (1085)
Texas (385)
Utah (80)
Washington State (323)
683,683 Results for "pluri inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
Pluri Inc., a leading biotechnology company that transforms cells into solutions, announced the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023.
June 6, 2024
·
7 min read
Business
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
Pluri Inc. announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.
March 6, 2024
·
6 min read
Pluri Inc. Announces 1-for-8 Reverse Share Split
Pluri Inc. announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024.
March 27, 2024
·
4 min read
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
Leading biotechnology company Pluri Inc. issued the following update from CEO and President, Yaky Yanay.
February 28, 2024
·
10 min read
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced leadership from its business verticals will be presenting at, and participating in, the following conferences.
March 28, 2024
·
5 min read
Engage with Pluri’s Talent: Exciting Conference Appearances Ahead
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced its participation in the following upcoming conferences.
March 19, 2024
·
2 min read
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Pluri Inc., a leading biotechnology company that transforms cells into solutions, launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors – a significant medical need which currently lacks effective treatments.
May 2, 2024
·
8 min read
Press Releases
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
October 28, 2024
·
7 min read
Press Releases
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
July 18, 2024
·
6 min read
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
Pluri Inc. announced that its CDMO division has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
March 14, 2024
·
5 min read
1 of 68,369
Next
